Vectus Biosystems (ASX:VBS) NonCurrent Deferred Revenue: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:VBS Vectus Biosystems Ltd ASX:VBS
9 GF Score
Price A$0.16
! 2 Warning Signs
View Full Analysis

What is Vectus Biosystems NonCurrent Deferred Revenue?

Vectus Biosystems ASX:VBS -6.06% 9 NonCurrent Deferred Revenue is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:VBS with a GF Score™ of 9/100. The stock has 2 warning signs investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Vectus Biosystems's non-current deferred revenue for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Vectus Biosystems NonCurrent Deferred Revenue Related Terms

Vectus Biosystems NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Vectus Biosystems's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vectus Biosystems NonCurrent Deferred Revenue Chart

Vectus Biosystems Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
NonCurrent Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vectus Biosystems Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:VBS
9GF Score
Vectus Biosystems Ltd ASX:VBS
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of A$0.00 Mil mean?
Vectus Biosystems (ASX:VBS) has a NonCurrent Deferred Revenue of A$0.00 Mil as of Dec. 2025. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Vectus Biosystems and its competitors.
Is Vectus Biosystems' NonCurrent Deferred Revenue too high?
Vectus Biosystems' current NonCurrent Deferred Revenue is A$0.00 Mil. Overall, Vectus Biosystems has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Vectus Biosystems' NonCurrent Deferred Revenue compare to VRTX and REGN?
Vectus Biosystems' NonCurrent Deferred Revenue of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Biotechnology company?
A good NonCurrent Deferred Revenue depends on the Biotechnology industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Vectus Biosystems and its competitors. Vectus Biosystems's current NonCurrent Deferred Revenue is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectus Biosystems stock overvalued right now?
Vectus Biosystems (ASX:VBS) has a current NonCurrent Deferred Revenue of A$0.00 Mil. The current NonCurrent Deferred Revenue is A$0.00 Mil. Vectus Biosystems' overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Vectus Biosystems (ASX:VBS), the current NonCurrent Deferred Revenue is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vectus Biosystems Business Description

Address 26-34 Dunning Avenue, Unit 5, Ground Floor, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
9GF Score

Get the complete analysis for ASX:VBS

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.16
Price